This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-07-3230v1 67/23/11102    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaelin, W. G. Articles by Mihich, E. Search for Related Content PubMed PubMed Citation Articles by Kaelin, W. G. Articles by Mihich, E.

Nineteenth Annual Pezcoller Symposium: Hypothesis-Driven Clinical Investigation in Cancer

¹ Dana-Farber Cancer Institute, Boston, Massachusetts; ² Memorial Sloan Kettering Cancer Center, New York, New York; and ³ Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Enrico Mihich, Experimental Therapeutics, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263. Phone: 716-845-3314; Fax: 716-845-3351; E-mail: enrico.mihich{at}roswellpark.org.

This symposium was held in Trento, Italy, from June 14 to 16, 2007, and was cochaired by William G. Kaelin, Enrico Mihich, and Charles L. Sawyers. A session was deveted to the proof of concept derived from successes in target-oriented therapeutics. Molecular targets must be identified in each patients because they are equally present in all patients with the same tumor type. A session was devoted to the identification of markers of drug effectiveness. Two sessions were focused on opportunities for developing new specific molecular target-oriented therapies. [Cancer Res 2007;67(23):11102–5]